Characterization and Comparison of the Gene Expression Profiles of Copaxone® and Mylan Glatiramer Acetate

被引：0
|
作者：
Smith, Jeffrey [1 ]
Hsu, Chun-Nan [2 ]
Lipsky, Peter [3 ]
机构：
[1] Mylan Labs, Morgantown, WV USA
[2] UC San Diego, Dept Biomed Informat, La Jolla, CA USA
[3] AMPEL BioSolut, Charlottesville, VA USA
来源：
NEUROLOGY | 2018年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1.376
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: Quantitative MR assessment
    Ge, Y
    Grossman, RI
    Udupa, JK
    Fulton, J
    Constantines, CS
    Gonzales-Scarano, F
    Babb, JS
    Mannon, LJ
    Kolson, DL
    Cohen, JA
    NEUROLOGY, 2000, 54 (07) : A86 - A87
  • [32] Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS - Quantitative MR assessment
    Ge, Y
    Grossman, RI
    Udupa, JK
    Fulton, J
    Constantinescu, CS
    Gonzales-Scarano, F
    Babb, JS
    Mannon, LJ
    Kolson, DL
    Cohen, JA
    NEUROLOGY, 2000, 54 (04) : 813 - 817
  • [33] Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis A pilot study
    Cinthia Farina
    Stefan Wagenpfeil
    Reinhard Hohlfeld
    Journal of Neurology, 2002, 249 : 1587 - 1592
  • [34] Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial
    Johnson, KP
    Brooks, BR
    Ford, CC
    Goodman, AD
    Lisak, RP
    Myers, LW
    Pruitt, AA
    Rizzo, MA
    Rose, JW
    Weiner, LP
    Wolinsky, JS
    MULTIPLE SCLEROSIS, 2003, 9 (06): : 585 - 591
  • [35] Cutaneous adverse events related to glatiramer acetate injection (copolymer-1, Copaxone®)
    Kluger, N.
    Thouvenot, E.
    Camu, W.
    Guillot, B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (11) : 1332 - 1333
  • [36] Gene expression analysis reveals functional pathways of glatiramer acetate activation
    Bakshi, Shlomo
    Chalifa-Caspi, Vered
    Plaschkes, Inbar
    Perevozkin, Igor
    Gurevich, Michael
    Schwartz, Riki
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (04) : 351 - 362
  • [37] Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis
    Sellebjerg, F.
    Hedegaard, C. J.
    Krakauer, M.
    Hesse, D.
    Lund, H.
    Nielsen, C. H.
    Sondergaard, H. B.
    Sorensen, P. S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (03) : 305 - 313
  • [38] Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use
    Wynn, Daniel R.
    MULTIPLE SCLEROSIS INTERNATIONAL, 2019, 2019
  • [39] Glatiramer acetate (Copaxone®) regulates nitric oxide and related cytokine secretion in experimental autoimmune encephalomyelitis
    Kayhan, B
    Aharoni, R
    Arnon, R
    IMMUNOLOGY LETTERS, 2003, 88 (03) : 185 - 192
  • [40] Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone®) injection for the treatment of multiple sclerosis
    Soos, N
    Shakery, K
    Mrowietz, U
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2004, 5 (05) : 357 - 359
12345